We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Colorectal Cancer - Pipeline Review, H1 2018

Published: June 2018
Pages: 2237
Code: E4D3AE845B96C78F9187DAE7D6211906
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 2,500.00
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide , provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.
Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide , provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 27, 132, 157, 16, 185, 32 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 30 and 3 molecules, respectively.
Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
  • - The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • - The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • - The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • - The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Companies Mentioned

3-V Biosciences Inc
3SBio Inc
4SC AG
AB Science SA
AbbVie Inc
AbGenomics International Inc
Abpro
Aclaris Therapeutics Inc
Adamed Sp z oo
Aduro BioTech Inc
Advenchen Laboratories LLC
AlfaSigma SpA
Alligator Bioscience AB
Allinky Biopharma
Amarin Corp Plc
amcure GmbH
Amgen Inc
Antibe Therapeutics Inc
APEIRON Biologics AG
Apexigen Inc
Aphios Corp
Aposense Ltd
Arcus Biosciences Inc
ARMO Biosciences Inc
ArQule Inc
Array BioPharma Inc
Asana BioSciences LLC
Ascelia Pharma AB
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Aurobindo Pharma Ltd
AVEO Pharmaceuticals Inc
B Cell Design SAS
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Hanmi Pharmaceutical Co Ltd
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Bionomics Ltd
Bionovis SA
Biotecnol Ltd
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Cancer Prevention Pharmaceuticals Inc
Cancer Research Technology Ltd
Cantargia AB
Carna Biosciences Inc
CaroGen Corp
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellix Bio Pvt Ltd
Celltrion Inc
Celyad SA
Checkmate Pharmaceuticals Inc
Chipscreen Biosciences Ltd
ChoDang Pharm Co Ltd
Chong Kun Dang Pharmaceutical Corp
Cinnagen Co
Cleveland BioLabs Inc
COARE Biotechnology Inc
Coherus BioSciences Inc
Compugen Ltd
Conatus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
CrystalGenomics Inc
Daiichi Sankyo Co Ltd
DanDrit Biotech A/S
Deciphera Pharmaceuticals LLC
Dr. Reddy's Laboratories Ltd
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Endor Nanotechnologies SL
EntreChem SL
Enzene Biosciences Ltd
Enzo Biochem Inc
EpiThany Inc
Etubics Corp
Exelixis Inc
Exicure Inc
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Formation Biologics Inc
Formosa Laboratories Inc
Forty Seven Inc
Fresenius SE & Co KGaA
Fujifilm Holdings Corporation
Fusion Antibodies Ltd
GamaMabs Pharma SA
GC Pharma
Gene Techno Science Co Ltd
Genentech Inc
Genmab A/S
Genoscience Pharma
Genzyme Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Glycostem Therapeutics BV
Glycotope GmbH
Handok Inc
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Heat Biologics Inc
Heidelberg Pharma AG
Hemispherx Biopharma Inc
Hercules Pharmaceuticals BV
Humanigen Inc
Hutchison MediPharma Ltd
iDD biotech SAS
Ideaya Biosciences Inc
Idera Pharmaceuticals Inc
Ignyta Inc
Ildong Pharmaceutical Co Ltd
Immodulon Therapeutics Ltd
Immunomedics Inc
Immunovative Therapies Ltd
Incanthera Ltd
Incyte Corp
Innate Pharma SA
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Interprotein Corp
Intezyne Technologies Inc
Ipsen SA
Isofol Medical AB
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kura Oncology Inc
Laboratorio ELEA SACIF y A
LipoMedix Pharmaceutical Inc
Loxo Oncology Inc
Luye Pharma Group Ltd
Mabion SA
mAbxience SA
MacroGenics Inc
Mantis Therapeutics BV
Marina Biotech Inc
Medesis Pharma SA
MediaPharma SRL
MediciNova Inc
MedImmune LLC
Medivir AB
MELEMA Pharma GmbH
Merck & Co Inc
Merck KGaA
Merus NV
MetaMax Ltd
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Moderna Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
Mologen AG
Morphotek Inc
Multimmune GmbH
Mycenax Biotech Inc
NantKwest Inc
Natco Pharma Ltd
NatureWise Biotech & Medicals Corp
Nektar Therapeutics
Neovacs SA
Nerviano Medical Sciences Srl
Nippon Kayaku Co Ltd
NormOxys Inc
Northwest Biotherapeutics Inc
Novartis AG
Noxxon Pharma AG
NuCana Plc
OBI Pharma Inc
Omnitura Therapeutics Inc
Oncology Research International Ltd
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
Otsuka Holdings Co Ltd
Oxford BioTherapeutics Ltd
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Pivotal BioSciences Inc
PlantForm Corp
Plexxikon Inc
Polaris Pharmaceuticals Inc
Precision Biologics Inc
Propanc Biopharma Inc
Protheragen Inc
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Puretech Health plc
R Pharm
Rafael Pharmaceuticals Inc
RedHill Biopharma Ltd
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Rgenix Inc
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt
Samumed LLC
Sanofi
Scancell Holdings Plc
Seattle Genetics Inc
Second Genome Inc
Selvita SA
Shanghai Henlius Biotech Co Ltd
Siamab Therapeutics Inc
Sichuan Kelun Pharmaceutical Co Ltd
Sierra Oncology Inc
Sillajen Biotherapeutics
Simcere Pharmaceutical Group
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
ST Pharm Co., Ltd.
Steba Biotech SA
Sublimity Therapeutics Ltd
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
SuviCa Inc
Symphogen A/S
Syndax Pharmaceuticals Inc
SynDevRx Inc
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Targovax ASA
Tarrex Biopharma Ltd
Tarveda Therapeutics Inc
Theralase Technologies Inc
Tocagen Inc
Tolero Pharmaceuticals Inc
TRACON Pharmaceuticals Inc
Trovagene Inc
United BioPharma Inc
Vaccinex Inc
VasGene Therapeutics Inc
Vaximm AG
Vincogen Corp
Vitality Biopharma Inc
WntResearch AB
Wuhan YZY Biopharma Co Ltd
XBiotech Inc
Xencor Inc
XuanZhu Pharma Co Ltd
Zelluna Immunotherapy AS
Zymeworks Inc

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics. Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Add to basket
  • Table of Contents
  • Table of Contents 2
  • Introduction 12
  • Colorectal Cancer - Overview 13
  • Colorectal Cancer - Therapeutics Development 14
  • Colorectal Cancer - Therapeutics Assessment 76
  • Colorectal Cancer - Companies Involved in Therapeutics Development 106
  • Colorectal Cancer - Drug Profiles 226
  • Colorectal Cancer - Dormant Projects 2137
  • Colorectal Cancer - Discontinued Products 2160
  • Colorectal Cancer - Product Development Milestones 2165
  • Appendix 2176
  • List of Tables
  • Number of Products under Development for Colorectal Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
  • Colorectal Cancer - Pipeline by 3SBio Inc, H1 2018
  • Colorectal Cancer - Pipeline by 4SC AG, H1 2018
  • Colorectal Cancer - Pipeline by AB Science SA, H1 2018
  • Colorectal Cancer - Pipeline by AbbVie Inc, H1 2018
  • Colorectal Cancer - Pipeline by AbGenomics International Inc, H1 2018
  • Colorectal Cancer - Pipeline by Abpro, H1 2018
  • Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H1 2018
  • Colorectal Cancer - Pipeline by Adamed Sp z oo, H1 2018
  • Colorectal Cancer - Pipeline by Aduro BioTech Inc, H1 2018
  • Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Colorectal Cancer - Pipeline by AlfaSigma SpA, H1 2018
  • Colorectal Cancer - Pipeline by Alligator Bioscience AB, H1 2018
  • Colorectal Cancer - Pipeline by Allinky Biopharma, H1 2018
  • Colorectal Cancer - Pipeline by Amarin Corp Plc, H1 2018
  • Colorectal Cancer - Pipeline by amcure GmbH, H1 2018
  • Colorectal Cancer - Pipeline by Amgen Inc, H1 2018
  • Colorectal Cancer - Pipeline by Antibe Therapeutics Inc, H1 2018
  • Colorectal Cancer - Pipeline by APEIRON Biologics AG, H1 2018
  • Colorectal Cancer - Pipeline by Apexigen Inc, H1 2018
  • Colorectal Cancer - Pipeline by Aphios Corp, H1 2018
  • Colorectal Cancer - Pipeline by Aposense Ltd, H1 2018
  • Colorectal Cancer - Pipeline by Arcus Biosciences Inc, H1 2018
  • Colorectal Cancer - Pipeline by ARMO Biosciences Inc, H1 2018
  • Colorectal Cancer - Pipeline by ArQule Inc, H1 2018
  • Colorectal Cancer - Pipeline by Array BioPharma Inc, H1 2018
  • Colorectal Cancer - Pipeline by Asana BioSciences LLC, H1 2018
  • Colorectal Cancer - Pipeline by Ascelia Pharma AB, H1 2018
  • Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
  • Colorectal Cancer - Pipeline by Astellas Pharma Inc, H1 2018
  • Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018
  • Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2018
  • Colorectal Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
  • Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H1 2018
  • Colorectal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
  • Colorectal Cancer - Pipeline by B Cell Design SAS, H1 2018
  • Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018
  • Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2018
  • Colorectal Cancer - Pipeline by Bayer AG, H1 2018
  • Colorectal Cancer - Pipeline by BeiGene Ltd, H1 2018
  • Colorectal Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018
  • Colorectal Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
  • Colorectal Cancer - Pipeline by Biocon Ltd, H1 2018
  • Colorectal Cancer - Pipeline by Bionomics Ltd, H1 2018
  • Colorectal Cancer - Pipeline by Bionovis SA, H1 2018
  • Colorectal Cancer - Pipeline by Biotecnol Ltd, H1 2018
  • Colorectal Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2018
  • Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Colorectal Cancer - Pipeline by Boston Biomedical Inc, H1 2018
  • Colorectal Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Colorectal Cancer - Pipeline by Calithera Biosciences Inc, H1 2018
  • Colorectal Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018
  • Colorectal Cancer - Pipeline by Cancer Research Technology Ltd, H1 2018
  • Colorectal Cancer - Pipeline by Cantargia AB, H1 2018
  • Colorectal Cancer - Pipeline by Carna Biosciences Inc, H1 2018
  • List of Figures
  • Number of Products under Development for Colorectal Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

Keywords
;